Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2684-2689

  Jones, T ^a   Tavakkol, A ^b  

^a J and S Studies Inc   (United States)

^b Topica Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LULICONAZOLE;

ABDOMINAL PAIN; ADULT; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTACT DERMATITIS; DISTAL SUBUNGUAL ONYCHOMYCOSIS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUS HEADACHE; STEADY STATE; TOENAIL ONYCHOMYCOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NAILS; ONYCHOMYCOSIS; PHARMACEUTICAL SOLUTIONS; TREATMENT OUTCOME;

EID: 84877857088     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02370-12     Document Type: Article

References (21)

1. Finch JJ, Warshaw EM. 2007. Toenail onychomycosis: Current and future treatment options. Dermatol. Ther. 20:31-46.
2. Tabolli S, Alessandroni L, Gaido J, Sampogna F, Di Pietro C, Abeni D. 2007. Health-related quality of life and nail disorders. Acta Derm. Venereol. 87:255-259.
3. Elewski BE. 1998. Onychomycosis: Pathogenesis, diagnosis, and management. Clin. Microbiol. Rev. 11:415-429.
4. Scher RK, Tavakkol A, Sigurgeirsson B, Hay RJ, Joseph WS, Tosti A, Fleckman P, Ghannoum M, Armstrong DG, Markinson BC, Elewski BE. 2007. Onychomycosis: Diagnosis and definition of cure. J. Am. Acad. Dermatol. 56:939-944.
5. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. 2010. Toenail onychomycosis: An important global disease burden. J. Clin. Pharm. Ther. 35:497-519.
6. Elewski BE. 2000. Onychomycosis. Treatment, quality of life, and economic issues. Am. J. Clin. Dermatol. 1:19-26.
7. Reich A, Szepietowski JC. 2011. Health-related quality of life in patients with nail disorders. Am. J. Clin. Dermatol. 12:313-320.
8. Elewski B, Tavakkol A. 2005. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: A proven reality. Ther. Clin. Risk Manag. 1:299-306.
9. Bohn M, Kraemer K. 2000. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J. Am. Podiatr. Med. Assoc. 90:491-494.
10. Gupta AK, Cooper EA. 2008. Update in antifungal therapy of dermatophytosis. Mycopathologia 166:353-367.
11. Gupta AK, Uro M, Cooper EA. 2010. Onychomycosis therapy: Past, present, future. J. Drugs Dermatol. 9:1109-1113.
12. Uchida K, Nishiyama Y, Yamaguchi H. 2004. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J. Infect. Chemother. 10:216-219.
13. Koga H, Nanjoh Y, Kaneda H, Yamaguchi H, Tsuboi R. 2012. Shortterm therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis. Antimicrob. Agents Chemother. 56:3138-3143.
14. Koga H, Tsuji Y, Inoue K, Kanai K, Majima T, Kasai T, Uchida K, Yamaguchi H. 2006. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J. Infect. Chemother. 12:163-165.
15. Koga H, Nanjoh Y, Makimura K, Tsuboi R. 2009. In vitro antifungal activities of luliconazole, a new topical imidazole. Med. Mycol. 47:640-647.
16. Korting HC, Schollmann C. 2009. The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes. J. Dtsch. Dermatol. Ges. 7:11-20.
17. Waldmeier F, Lehman P, Franz T, Pfister W. 2009. Terbinafine HCl in a novel alcohol vehicle permeates the human nail and achieves therapeutic concentrations in the nail plate and nail bed. J. Am. Acad. Dermatol. 60:AB111.
18. Pola Chemical Industry (currently Pola Pharma). 2005. Lulicon cream 1% and Lulicon solution 1% package insert. Pola Pharma, Yokohama, Japan.
19. Crean C, Akinori A, Oh A, Kang R. 2013. Minimal systemic exposure of a new topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment. J. Am. Acad. Dermatol. 68(Suppl.):AB107.
20. Sakamoto M, Kodera N, Sugimoto N, Pillai R. 2013. Efinaconazole 10% solution a new triazole antifungal developed for topical onychomycosis treatment: Nail penetration and systemic absorption. J. Am. Acad. Dermatol. 68(Suppl.):AB104.
21. Aventis Pharmaceuticals Inc. 2004. PENLAC nail lacquer topical solution 8% package insert. Aventis Pharmaceuticals Inc., Lansdale, PA.